Yahoo
NasdaqGS - Delayed Quote USD

Vaxcyte, Inc. (PCVX)

60.81 +0.26 (+0.43%)
At close: April 22 at 4:00:00 PM EDT
60.68 -0.13 (-0.21%)
Pre-Market: 6:06:02 AM EDT
Trade Vaxcyte on Coinbase
Chart Range Bar
Loading chart for PCVX
  • Previous Close 60.55
  • Open 61.01
  • Bid 60.68 x 100
  • Ask 60.96 x 100
  • Day's Range 60.27 - 61.82
  • 52 Week Range 28.09 - 65.00
  • Volume 801,056
  • Avg. Volume 1,400,139
  • Market Cap (intraday) 8.83B
  • Beta (5Y Monthly) 1.39
  • PE Ratio (TTM) --
  • EPS (TTM) -5.63
  • Earnings Date (est.) May 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 109.00

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

vaxcyte.com

507

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: PCVX

Trailing total returns as of 4/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PCVX
31.79%
S&P 500 (^GSPC)
4.27%

1-Year Return

PCVX
94.53%
S&P 500 (^GSPC)
34.99%

3-Year Return

PCVX
34.77%
S&P 500 (^GSPC)
72.68%

5-Year Return

PCVX
213.78%
S&P 500 (^GSPC)
72.62%

Earnings Trends: PCVX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -246.51M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-200M
-150M
-100M
-50M
0

Analyst Insights: PCVX

View More

Analyst Price Targets

67.00
109.00 Average
60.81 Current
163.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 2/26/2026
Analyst BTIG
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 85 -> 89

Statistics: PCVX

View More

Valuation Measures

Annual
As of 4/22/2026
  • Market Cap

    8.75B

  • Enterprise Value

    7.31B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.26

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -17.72%

  • Return on Equity (ttm)

    -25.59%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -766.63M

  • Diluted EPS (ttm)

    -5.63

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.56B

  • Total Debt/Equity (mrq)

    4.37%

  • Levered Free Cash Flow (ttm)

    -430.85M

Compare To: PCVX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: PCVX

Fair Value

60.81 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: